| Market Cap | 217.92B | P/E | 46.07 | EPS this Y | - | Ern Qtrly Grth | 6.50% |
| Income | 5.95B | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -2.00% |
| Sales | 45.81B | PEG | - | EPS past 5Y | - | 200D Avg Chg | 2.00% |
| Dividend | 2.00% | Price/Book | 5.77 | EPS next 5Y | - | 52W High Chg | -9.00% |
| Recommedations | - | Quick Ratio | 0.58 | Shares Outstanding | 1.55B | 52W Low Chg | 33.00% |
| Insider Own | 0.23% | ROA | 6.60% | Shares Float | 1.54B | Beta | 0.19 |
| Inst Own | 50.79% | ROE | 15.64% | Shares Shorted/Prior | -/- | Price | 139.13 |
| Gross Margin | 82.45% | Profit Margin | 13.00% | Avg. Volume | 2,903 | Target Price | - |
| Oper. Margin | 16.92% | Earnings Date | - | Volume | 477 | Change | -2.61% |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.